Opthea Ltd at SVB Securities Global Biopharma Conference (Virtual) Transcript
Good afternoon, everyone. Welcome back to the next session of the SVB Securities Global Biopharma Conference. My name is Rudy Li, biopharma analyst of the SVB Securities equity research team.
So I'm very happy today to introduce management team of Opthea for a presentation to talk about the story of the company. Joining us today are Megan Baldwin, the CEO; and Timothy Morris, the CFO of the company. For the investors who join us today, feel free to submit any questions on the webcast.
Well, thanks for joining us, Megan. Now, the floor is yours.
Thanks, very much, Rudy, and thanks very much for the opportunity to take you through the Opthea story today. I'm going to tell you about our novel therapy, which is OPT-302. It's a trap molecule targeting novel members of the VEGF family, which is being used as a treatment in combination with standard of care therapies to give patients a better opportunity to improve visual acuity when they suffer from wet age-related
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
